Floatz logo

Therapeutic Asset Ratings

181 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Eb-G3B7-Nk Dual-Target Car-Nk Cells
Metastatic Liver Cancer
Beijing BiotechP1/2CCC (48)
Eb-Mf-Car-Nk-01
Malignant Pleural Mesotheliomas
Beijing BiotechP1/2CCC (48)
Eb-Nk-301
TROP2-Expressing Solid Tumors
Beijing BiotechP1/2CCC (48)
Egfr/Her2 Dual-Target Car-Nk Cells
Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Beijing BiotechP1/2CCC (48)
Fludarabine
Bladder Cancer
Beijing BiotechP1/2CCC (48)
Fludarabine
Castration-Resistant Prostate Carcinoma
Beijing BiotechP1/2CCC (48)
Fludarabine
Ganglioneuroblastoma
Beijing BiotechP1/2CCC (48)
Fludarabine
Gastroesophageal Junction Adenocarcinoma
Beijing BiotechP1/2CCC (48)
Fludarabine
Malignant Pleural Mesotheliomas
Beijing BiotechP1/2CCC (48)
Fludarabine
Recurrent or Refractory Disease After Standard Therapies
Beijing BiotechP1/2CCC (48)
Fludarabine
TROP2-Expressing Solid Tumors
Beijing BiotechP1/2CCC (48)
Autologous Bcma/Cd19 Dual-Target Car-T Module
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Beijing BiotechP1/2CC (47)
Autologous Bcma/Cd19 Dual-Target Car-T Module
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL
Beijing BiotechP1/2CC (47)
Autologous Bcma/Cd19 Dual-Target Car-T Module
Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Beijing BiotechP1/2CC (47)
Autologous Bcma/Cd38 Dual-Target Car-T Module
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Beijing BiotechP1/2CC (47)
Autologous Bcma/Cd38 Dual-Target Car-T Module
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL
Beijing BiotechP1/2CC (47)
Autologous Bcma/Cd38 Dual-Target Car-T Module
Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Beijing BiotechP1/2CC (47)
Autologous Bcma/Gprc5D Dual-Target Car-T
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Beijing BiotechP1/2CC (47)
Autologous Bcma/Gprc5D Dual-Target Car-T
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL
Beijing BiotechP1/2CC (47)
Autologous Bcma/Gprc5D Dual-Target Car-T
Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Beijing BiotechP1/2CC (47)
Autologous Cd19/Cd20 Dual-Target Car-T Module
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Beijing BiotechP1/2CC (47)
Autologous Cd19/Cd20 Dual-Target Car-T Module
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL
Beijing BiotechP1/2CC (47)
Autologous Cd19/Cd20 Dual-Target Car-T Module
Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Beijing BiotechP1/2CC (47)
Autologous Cd19/Cd22 Dual-Target Car-T Module
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Beijing BiotechP1/2CC (47)
Autologous Cd19/Cd22 Dual-Target Car-T Module
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL
Beijing BiotechP1/2CC (47)
Showing 51 to 75 of 181 assets
PreviousPage 3 of 8Next